{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:35:04Z","timestamp":1789011304993,"version":"build-2803163510"},"reference-count":72,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"abstract":"\n Context<\/jats:italic>\n .\u2014Methods for plasma cell enrichment of bone marrow (BM) specimens can increase the sensitivity of fluorescence in situ hybridization (FISH) for detecting cytogenomic abnormalities. There are no published reports using these methods to evaluate high-risk cytogenomic abnormalities in patients with plasma cell neoplasms (PCNs) after therapy.\n <\/jats:p>\n \n Objective<\/jats:italic>\n .\u2014To evaluate the utility of plasma cell enrichment combined with FISH for detection of high-risk cytogenomic abnormalities in patients with PCNs after therapy.\n <\/jats:p>\n \n Design<\/jats:italic>\n .\u2014Twenty-eight patients with PCNs, of whom 22 received treatment, were included in this study. Plasma cells were enriched in BM aspirates by using a magnetic cell-sorting procedure to select CD138\n +<\/jats:sup>\n cells. Probes were chosen to assess for del(17p13\/\n TP53<\/jats:italic>\n ), del(13q14\/\n RB1<\/jats:italic>\n ), 1q21\/\n CKS1B<\/jats:italic>\n gain,\n IgH\/FGFR3<\/jats:italic>\n , and\n IgH\/MAF<\/jats:italic>\n . Clinicopathologic data were collected during clinical follow-up after plasma cell enrichment.\n <\/jats:p>\n \n Results<\/jats:italic>\n .\u2014Plasma cells in nonenriched BM specimens ranged from 1% to 28% (median, 8%) compared with 28% to 96% (median, 73%) in enriched BM specimens (\n P<\/jats:italic>\n < .001). In a subset of treated patients in clinical remission, FISH detected high-risk cytogenomic abnormalities only in plasma cell\u2013enriched samples. This approach also detected abnormalities in cases of solitary plasmacytoma and monoclonal gammopathy of undetermined significance.\n <\/jats:p>\n \n Conclusions<\/jats:italic>\n .\u2014Plasma cell enrichment of BM specimens increases FISH sensitivity for detecting high-risk cytogenomic abnormalities, particularly in treated patients, and these results, in combination with clinical follow-up data, can be of value to improve risk stratification and patient management.\n <\/jats:p>","DOI":"10.5858\/arpa.2012-0209-oa","type":"journal-article","created":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T14:08:53Z","timestamp":1367244533000},"page":"625-631","source":"Crossref","is-referenced-by-count":29,"title":["Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms"],"prefix":"10.5858","volume":"137","author":[{"given":"Gary","family":"Lu","sequence":"first","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Muddasani","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne V.","family":"Abruzzo","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. James","family":"You","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Claudia","family":"Glitza","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"From the Departments of Hematopathology (Drs Lu, Abruzzo, You, Chen, and Medeiros, and Ms Muddasani), Myeloma (Dr Orlowski), and Stem Cell Transplantation (Drs Qazilbash and Glitza) and the Cytogenetic Technology Program (Dr Zhao), The University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Biostatistics, The University of Texas School of Public Health, Houston, Texas (Mr Wang)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"11","key":"i1543-2165-137-5-625-b01","series-title":"Eur J Cancer","first-page":"1520","article-title":"Cytogenetics and molecular cytogenetics in multiple myeloma","volume":"42","author":"Liebisch\n P,","year":"2006","unstructured":"Liebisch\n P, \n \n Dohner\n H. \n \n Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer. 2006;42(11):1520\u20131596."},{"issue":"3","key":"i1543-2165-137-5-625-b02","series-title":"Cancer","first-page":"601","article-title":"Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia","volume":"97","author":"Rasillo\n A,","year":"2003","unstructured":"Rasillo\n A, \n \n Tabernero\n MD, \n \n S\u00e1nchez\n ML, \n et al\n . Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer. 2003;97(3):601\u2013609."},{"issue":"11","key":"i1543-2165-137-5-625-b03","series-title":"Eur J Cancer","first-page":"1510","article-title":"Conventional diagnostics in multiple myeloma","volume":"42","year":"2006","unstructured":"San Miguel JF, Guti\u00e9rrez NC, Mateo G. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42(11):1510\u20131519."},{"issue":"3","key":"i1543-2165-137-5-625-b04","series-title":"Blood","first-page":"607","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima\n T,","year":"2004","unstructured":"Hideshima\n T, \n \n Bergsagel\n PL, \n \n Kuehl\n WM, \n \n Anderson\n KC. \n \n Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104(3):607\u2013618."},{"issue":"4","key":"i1543-2165-137-5-625-b05","series-title":"Cytometry B Clin Cytom","first-page":"231","article-title":"Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology","volume":"78","author":"Cannizzo\n E,","year":"2010","unstructured":"Cannizzo\n E, \n \n Bellio\n E, \n \n Sohani\n AR, \n et al\n . Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom. 2010;78(4):231\u2013238."},{"issue":"10","key":"i1543-2165-137-5-625-b06","series-title":"Mod Pathol","first-page":"1217","article-title":"Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray","volume":"17","author":"Lin\n P,","year":"2004","unstructured":"Lin\n P, \n \n Mahdavy\n M, \n \n Zhan\n F, \n et al\n . Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004;17(10):1217\u20131222."},{"issue":"40","key":"i1543-2165-137-5-625-b07","series-title":"Oncogene","first-page":"5611","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel\n PL,","year":"2001","unstructured":"Bergsagel\n PL, \n \n Kuehl\n WM. \n \n Chromosome translocations in multiple myeloma. Oncogene. 2001;20(40):5611\u20135622."},{"issue":"6","key":"i1543-2165-137-5-625-b08","series-title":"Blood","first-page":"2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau\n H,","year":"2002","unstructured":"Avet-Loiseau\n H, \n \n Facon\n T, \n \n Grosbois\n B, \n et al\n . Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185\u20132191."},{"issue":"11","key":"i1543-2165-137-5-625-b09","series-title":"Leukemia","first-page":"1879","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann\n H,","year":"2004","unstructured":"Kaufmann\n H, \n \n Ackermann\n J, \n \n Baldia\n C, \n et al\n . Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004;18(11):1879\u20131882."},{"issue":"12","key":"i1543-2165-137-5-625-b10","series-title":"Leukemia","first-page":"2210","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca\n R,","year":"2009","unstructured":"Fonseca\n R, \n \n Bergsagel\n PL, \n \n Drach\n J, \n et al\n . International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12): 2210\u20132221."},{"issue":"1","key":"i1543-2165-137-5-625-b11","series-title":"Blood","first-page":"217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy\n J\n Jr,","year":"2001","unstructured":"Shaughnessy\n J\n Jr, \n \n Gabrea\n A, \n \n Qi\n Y, \n et al\n . Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98 (1):217\u2013223."},{"issue":"1","key":"i1543-2165-137-5-625-b12","series-title":"Exp Hematol","first-page":"78","article-title":"Identification of primary MAFB target genes in multiple myeloma","volume":"37","author":"Van Stralen\n E,","year":"2009","unstructured":"Van Stralen\n E, \n \n van de Wetering\n M, \n \n Agnelli\n L, \n \n Neri\n A, \n \n Clevers\n HC, \n \n Bast\n BJ. \n \n Identification of primary MAFB target genes in multiple myeloma. Exp Hematol. 2009;37(1):78\u201386."},{"issue":"4","key":"i1543-2165-137-5-625-b13","series-title":"Leukemia","first-page":"801","article-title":"MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients","volume":"23","author":"Stralen\n E,","year":"2009","unstructured":"Stralen\n E, \n \n Leguit\n RJ, \n \n Begthel\n H, \n et al\n . MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. Leukemia. 2009;23(4):801\u2013803."},{"issue":"1\u20133","key":"i1543-2165-137-5-625-b14","series-title":"FEBS Lett","first-page":"23","article-title":"Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development","volume":"565","author":"Petersen\n HH,","year":"2004","unstructured":"Petersen\n HH, \n \n Hilpert\n J, \n \n Jacobsen\n C, \n \n Lauwers\n A, \n \n Roebroek\n AJ, \n \n Willnow\n TE. \n \n Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development. FEBS Lett. 2004;565(1\u20133):23\u201327."},{"issue":"8","key":"i1543-2165-137-5-625-b15","series-title":"Blood","first-page":"2583","article-title":"Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome","volume":"94","author":"Avet-Loiseau\n H,","year":"1999","unstructured":"Avet-Loiseau\n H, \n \n Li\n JY, \n \n Morineau\n N, \n et al\n . Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood. 1999;94(8):2583\u20132589."},{"issue":"6","key":"i1543-2165-137-5-625-b16","series-title":"Leukemia","first-page":"981","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca\n R,","year":"2001","unstructured":"Fonseca\n R, \n \n Oken\n MM, \n \n Harrington\n D, \n et al\n . Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15(6):981\u2013986."},{"issue":"1","key":"i1543-2165-137-5-625-b17","series-title":"Cancer Genet","first-page":"3","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer\n JR.","year":"2011","unstructured":"Sawyer\n JR. \n \n The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3\u201312."},{"issue":"7","key":"i1543-2165-137-5-625-b18","series-title":"Genes Chromosomes Cancer","first-page":"624","article-title":"Frequent upregulation of MYC in plasma cell leukemia","volume":"48","author":"Chiecchio\n L,","year":"2009","unstructured":"Chiecchio\n L, \n \n Dagrada\n GP, \n \n White\n HE, \n et al\n . Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48(7):624\u2013636."},{"issue":"6","key":"i1543-2165-137-5-625-b19","series-title":"Leukemia","first-page":"1026","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng\n WJ,","year":"2011","unstructured":"Chng\n WJ, \n \n Huang\n GF, \n \n Chung\n TH, \n et al\n . Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25(6):1026\u20131035."},{"issue":"1","key":"i1543-2165-137-5-625-b20","series-title":"Bone Marrow Transplant","first-page":"117","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang\n H,","year":"2010","unstructured":"Chang\n H, \n \n Qi\n X, \n \n Jiang\n A, \n et al\n . 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2010;45(1):117\u2013121."},{"issue":"1","key":"i1543-2165-137-5-625-b21","series-title":"Br J Haematol","first-page":"51","article-title":"Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma","volume":"139","author":"Chang\n H,","year":"2007","unstructured":"Chang\n H, \n \n Ning\n Y, \n \n Qi\n X, \n et al\n . Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol. 2007;139(1):51\u201354."},{"issue":"4","key":"i1543-2165-137-5-625-b22","series-title":"Biol Blood Marrow Transplant","first-page":"548","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec\n P,","year":"2010","unstructured":"Nemec\n P, \n \n Zemanova\n Z, \n \n Greslikova\n H, \n et al\n . Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548\u2013554."},{"issue":"1","key":"i1543-2165-137-5-625-b23","series-title":"Leuk Res","first-page":"95","article-title":"Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains","volume":"35","author":"Chang\n H,","year":"2011","unstructured":"Chang\n H, \n \n Trieu\n Y, \n \n Qi\n X, \n et al\n . Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res. 2011;35(1):95\u201398."},{"issue":"6","key":"i1543-2165-137-5-625-b24","series-title":"Hum Pathol","first-page":"858","article-title":"Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib","volume":"43","author":"Chen\n MH,","year":"2012","unstructured":"Chen\n MH, \n \n Qi\n C, \n \n Reece\n D, \n \n Chang\n H. \n \n Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib. Hum Pathol. 2012;43(6):858\u2013864."},{"issue":"11","key":"i1543-2165-137-5-625-b25","series-title":"Genes Chromosomes Cancer","first-page":"765","article-title":"NCRI Haematology Oncology Studies Group: the clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy","volume":"50","author":"Boyd\n KD,","year":"2011","unstructured":"Boyd\n KD, \n \n Ross\n FM, \n \n Tapper\n WJ, \n et al\n . NCRI Haematology Oncology Studies Group: the clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011;50(11):765\u2013774."},{"issue":"7","key":"i1543-2165-137-5-625-b26","series-title":"J Clin Oncol","first-page":"2659","article-title":"Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants","volume":"15","author":"Tricot\n G,","year":"1997","unstructured":"Tricot\n G, \n \n Sawyer\n JR, \n \n Jagannath\n S, \n et al\n . Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15(7):2659\u20132666."},{"issue":"1","key":"i1543-2165-137-5-625-b27","series-title":"Am J Hematol","first-page":"57","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar\n SV.","year":"2011","unstructured":"Rajkumar\n SV. \n \n Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(1):57\u201365."},{"issue":"6","key":"i1543-2165-137-5-625-b28","series-title":"Am J Clin Pathol","first-page":"895","article-title":"Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow","volume":"125","author":"Zhao\n X,","year":"2006","unstructured":"Zhao\n X, \n \n Huang\n Q, \n \n Slovak\n M, \n \n Weiss\n L. \n \n Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol. 2006;125(6):895\u2013904."},{"issue":"2","key":"i1543-2165-137-5-625-b29","series-title":"Cancer Genet Cytogenet","first-page":"99","article-title":"Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype\/genotype fluorescence in situ hybridization","volume":"158","author":"Slovak\n ML,","year":"2005","unstructured":"Slovak\n ML, \n \n Bedell\n V, \n \n Pagel\n K, \n et al\n . Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype\/genotype fluorescence in situ hybridization. Cancer Genet Cytogenet. 2005;158(2):99\u2013109."},{"issue":"2","key":"i1543-2165-137-5-625-b30","series-title":"Cancer Genet Cytogenet","first-page":"112","article-title":"Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment","volume":"189","author":"Pozdnyakova\n O,","year":"2009","unstructured":"Pozdnyakova\n O, \n \n Crowley-Larsen\n P, \n \n Zota\n V, \n et al\n . Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment. Cancer Genet Cytogenet. 2009;189(2):112\u2013117."},{"key":"i1543-2165-137-5-625-b31","series-title":"Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed","first-page":"200","article-title":"Plasma cell neoplasms","author":"McKenna\n RW,","year":"2008","unstructured":"McKenna\n RW, \n \n Kyle\n RA, \n \n Kuehl\n WM, \n et al\n . Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press;2008:200\u2013213. World Health Organization Classification of Tumours; vol 2."},{"key":"i1543-2165-137-5-625-b32","series-title":"Am J Clin Pathol","first-page":"391","article-title":"Chromosome 20q deletion: a recurrent cytogenetic abnormality in chronic myelogenous leukemia patients in remission","volume":"135","author":"Sun\n J,","year":"2011","unstructured":"Sun\n J, \n \n Yin\n C, \n \n Cui\n W, \n \n Chen\n SS, \n \n Medeiros\n LJ, \n \n Lu\n G. \n \n Chromosome 20q deletion: a recurrent cytogenetic abnormality in chronic myelogenous leukemia patients in remission. Am J Clin Pathol. 2011;135:391\u2013397."},{"issue":"1","key":"i1543-2165-137-5-625-b33","series-title":"Cancer Genet Cytogenet","first-page":"56","article-title":"Genetic and immunophenotypic profile of IgH rearrangement detected by FISH in 149 cases of chronic lymphocytic leukemia","volume":"196","author":"Lu\n G,","year":"2010","unstructured":"Lu\n G, \n \n Kong\n Y, \n \n Yue\n C. \n \n Genetic and immunophenotypic profile of IgH rearrangement detected by FISH in 149 cases of chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2010;196(1):56\u201363."},{"issue":"5","key":"i1543-2165-137-5-625-b34","series-title":"Int J Lab Hematol","first-page":"545","article-title":"Assessment of bone marrow plasma cells by flow cytometric and fluorescence in situ hybridization evaluations in 244 cases of plasma cell neoplasms","volume":"3","author":"Lu\n G,","year":"2011","unstructured":"Lu\n G, \n \n Zhang\n XX, \n \n You\n J, \n \n Chen\n W. \n \n Assessment of bone marrow plasma cells by flow cytometric and fluorescence in situ hybridization evaluations in 244 cases of plasma cell neoplasms. Int J Lab Hematol. 2011;3(5):545\u2013550."},{"issue":"suppl 4","key":"i1543-2165-137-5-625-b35","series-title":"Clin Lymphoma Myeloma","first-page":"S170","article-title":"Individualizing therapy using molecular markers in multiple myeloma","author":"Bergsagel\n PL.","year":"2007","unstructured":"Bergsagel\n PL. \n \n Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma. 2007;(suppl 4):S170\u2013S174."},{"issue":"5","key":"i1543-2165-137-5-625-b36","series-title":"Int J Hematol","first-page":"516","article-title":"Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed\/refractory multiple myeloma","volume":"95","author":"Kiyota\n M,","year":"2012","unstructured":"Kiyota\n M, \n \n Kobayashi\n T, \n \n Fuchida\n S, \n et al\n . Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed\/refractory multiple myeloma. Int J Hematol. 2012;95(5):516\u2013526."},{"issue":"11","key":"i1543-2165-137-5-625-b01","series-title":"Eur J Cancer","first-page":"1520","article-title":"Cytogenetics and molecular cytogenetics in multiple myeloma","volume":"42","author":"Liebisch\n P,","year":"2006","unstructured":"Liebisch\n P, \n \n Dohner\n H. \n \n Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer. 2006;42(11):1520\u20131596."},{"issue":"3","key":"i1543-2165-137-5-625-b02","series-title":"Cancer","first-page":"601","article-title":"Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia","volume":"97","author":"Rasillo\n A,","year":"2003","unstructured":"Rasillo\n A, \n \n Tabernero\n MD, \n \n S\u00e1nchez\n ML, \n et al\n . Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer. 2003;97(3):601\u2013609."},{"issue":"11","key":"i1543-2165-137-5-625-b03","series-title":"Eur J Cancer","first-page":"1510","article-title":"Conventional diagnostics in multiple myeloma","volume":"42","year":"2006","unstructured":"San Miguel JF, Guti\u00e9rrez NC, Mateo G. Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42(11):1510\u20131519."},{"issue":"3","key":"i1543-2165-137-5-625-b04","series-title":"Blood","first-page":"607","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima\n T,","year":"2004","unstructured":"Hideshima\n T, \n \n Bergsagel\n PL, \n \n Kuehl\n WM, \n \n Anderson\n KC. \n \n Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104(3):607\u2013618."},{"issue":"4","key":"i1543-2165-137-5-625-b05","series-title":"Cytometry B Clin Cytom","first-page":"231","article-title":"Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology","volume":"78","author":"Cannizzo\n E,","year":"2010","unstructured":"Cannizzo\n E, \n \n Bellio\n E, \n \n Sohani\n AR, \n et al\n . Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom. 2010;78(4):231\u2013238."},{"issue":"10","key":"i1543-2165-137-5-625-b06","series-title":"Mod Pathol","first-page":"1217","article-title":"Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray","volume":"17","author":"Lin\n P,","year":"2004","unstructured":"Lin\n P, \n \n Mahdavy\n M, \n \n Zhan\n F, \n et al\n . Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004;17(10):1217\u20131222."},{"issue":"40","key":"i1543-2165-137-5-625-b07","series-title":"Oncogene","first-page":"5611","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel\n PL,","year":"2001","unstructured":"Bergsagel\n PL, \n \n Kuehl\n WM. \n \n Chromosome translocations in multiple myeloma. Oncogene. 2001;20(40):5611\u20135622."},{"issue":"6","key":"i1543-2165-137-5-625-b08","series-title":"Blood","first-page":"2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau\n H,","year":"2002","unstructured":"Avet-Loiseau\n H, \n \n Facon\n T, \n \n Grosbois\n B, \n et al\n . Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185\u20132191."},{"issue":"11","key":"i1543-2165-137-5-625-b09","series-title":"Leukemia","first-page":"1879","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann\n H,","year":"2004","unstructured":"Kaufmann\n H, \n \n Ackermann\n J, \n \n Baldia\n C, \n et al\n . Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004;18(11):1879\u20131882."},{"issue":"12","key":"i1543-2165-137-5-625-b10","series-title":"Leukemia","first-page":"2210","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca\n R,","year":"2009","unstructured":"Fonseca\n R, \n \n Bergsagel\n PL, \n \n Drach\n J, \n et al\n . International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12): 2210\u20132221."},{"issue":"1","key":"i1543-2165-137-5-625-b11","series-title":"Blood","first-page":"217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy\n J\n Jr,","year":"2001","unstructured":"Shaughnessy\n J\n Jr, \n \n Gabrea\n A, \n \n Qi\n Y, \n et al\n . Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98 (1):217\u2013223."},{"issue":"1","key":"i1543-2165-137-5-625-b12","series-title":"Exp Hematol","first-page":"78","article-title":"Identification of primary MAFB target genes in multiple myeloma","volume":"37","author":"Van Stralen\n E,","year":"2009","unstructured":"Van Stralen\n E, \n \n van de Wetering\n M, \n \n Agnelli\n L, \n \n Neri\n A, \n \n Clevers\n HC, \n \n Bast\n BJ. \n \n Identification of primary MAFB target genes in multiple myeloma. Exp Hematol. 2009;37(1):78\u201386."},{"issue":"4","key":"i1543-2165-137-5-625-b13","series-title":"Leukemia","first-page":"801","article-title":"MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients","volume":"23","author":"Stralen\n E,","year":"2009","unstructured":"Stralen\n E, \n \n Leguit\n RJ, \n \n Begthel\n H, \n et al\n . MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. Leukemia. 2009;23(4):801\u2013803."},{"issue":"1\u20133","key":"i1543-2165-137-5-625-b14","series-title":"FEBS Lett","first-page":"23","article-title":"Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development","volume":"565","author":"Petersen\n HH,","year":"2004","unstructured":"Petersen\n HH, \n \n Hilpert\n J, \n \n Jacobsen\n C, \n \n Lauwers\n A, \n \n Roebroek\n AJ, \n \n Willnow\n TE. \n \n Low-density lipoprotein receptor-related protein interacts with MafB, a regulator of hindbrain development. FEBS Lett. 2004;565(1\u20133):23\u201327."},{"issue":"8","key":"i1543-2165-137-5-625-b15","series-title":"Blood","first-page":"2583","article-title":"Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome","volume":"94","author":"Avet-Loiseau\n H,","year":"1999","unstructured":"Avet-Loiseau\n H, \n \n Li\n JY, \n \n Morineau\n N, \n et al\n . Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood. 1999;94(8):2583\u20132589."},{"issue":"6","key":"i1543-2165-137-5-625-b16","series-title":"Leukemia","first-page":"981","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca\n R,","year":"2001","unstructured":"Fonseca\n R, \n \n Oken\n MM, \n \n Harrington\n D, \n et al\n . Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15(6):981\u2013986."},{"issue":"1","key":"i1543-2165-137-5-625-b17","series-title":"Cancer Genet","first-page":"3","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer\n JR.","year":"2011","unstructured":"Sawyer\n JR. \n \n The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3\u201312."},{"issue":"7","key":"i1543-2165-137-5-625-b18","series-title":"Genes Chromosomes Cancer","first-page":"624","article-title":"Frequent upregulation of MYC in plasma cell leukemia","volume":"48","author":"Chiecchio\n L,","year":"2009","unstructured":"Chiecchio\n L, \n \n Dagrada\n GP, \n \n White\n HE, \n et al\n . Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48(7):624\u2013636."},{"issue":"6","key":"i1543-2165-137-5-625-b19","series-title":"Leukemia","first-page":"1026","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng\n WJ,","year":"2011","unstructured":"Chng\n WJ, \n \n Huang\n GF, \n \n Chung\n TH, \n et al\n . Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25(6):1026\u20131035."},{"issue":"1","key":"i1543-2165-137-5-625-b20","series-title":"Bone Marrow Transplant","first-page":"117","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang\n H,","year":"2010","unstructured":"Chang\n H, \n \n Qi\n X, \n \n Jiang\n A, \n et al\n . 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2010;45(1):117\u2013121."},{"issue":"1","key":"i1543-2165-137-5-625-b21","series-title":"Br J Haematol","first-page":"51","article-title":"Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma","volume":"139","author":"Chang\n H,","year":"2007","unstructured":"Chang\n H, \n \n Ning\n Y, \n \n Qi\n X, \n et al\n . Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol. 2007;139(1):51\u201354."},{"issue":"4","key":"i1543-2165-137-5-625-b22","series-title":"Biol Blood Marrow Transplant","first-page":"548","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec\n P,","year":"2010","unstructured":"Nemec\n P, \n \n Zemanova\n Z, \n \n Greslikova\n H, \n et al\n . Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548\u2013554."},{"issue":"1","key":"i1543-2165-137-5-625-b23","series-title":"Leuk Res","first-page":"95","article-title":"Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains","volume":"35","author":"Chang\n H,","year":"2011","unstructured":"Chang\n H, \n \n Trieu\n Y, \n \n Qi\n X, \n et al\n . Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res. 2011;35(1):95\u201398."},{"issue":"6","key":"i1543-2165-137-5-625-b24","series-title":"Hum Pathol","first-page":"858","article-title":"Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib","volume":"43","author":"Chen\n MH,","year":"2012","unstructured":"Chen\n MH, \n \n Qi\n C, \n \n Reece\n D, \n \n Chang\n H. \n \n Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib. Hum Pathol. 2012;43(6):858\u2013864."},{"issue":"11","key":"i1543-2165-137-5-625-b25","series-title":"Genes Chromosomes Cancer","first-page":"765","article-title":"NCRI Haematology Oncology Studies Group: the clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy","volume":"50","author":"Boyd\n KD,","year":"2011","unstructured":"Boyd\n KD, \n \n Ross\n FM, \n \n Tapper\n WJ, \n et al\n . NCRI Haematology Oncology Studies Group: the clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011;50(11):765\u2013774."},{"issue":"7","key":"i1543-2165-137-5-625-b26","series-title":"J Clin Oncol","first-page":"2659","article-title":"Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants","volume":"15","author":"Tricot\n G,","year":"1997","unstructured":"Tricot\n G, \n \n Sawyer\n JR, \n \n Jagannath\n S, \n et al\n . Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15(7):2659\u20132666."},{"issue":"1","key":"i1543-2165-137-5-625-b27","series-title":"Am J Hematol","first-page":"57","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar\n SV.","year":"2011","unstructured":"Rajkumar\n SV. \n \n Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(1):57\u201365."},{"issue":"6","key":"i1543-2165-137-5-625-b28","series-title":"Am J Clin Pathol","first-page":"895","article-title":"Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow","volume":"125","author":"Zhao\n X,","year":"2006","unstructured":"Zhao\n X, \n \n Huang\n Q, \n \n Slovak\n M, \n \n Weiss\n L. \n \n Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol. 2006;125(6):895\u2013904."},{"issue":"2","key":"i1543-2165-137-5-625-b29","series-title":"Cancer Genet Cytogenet","first-page":"99","article-title":"Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype\/genotype fluorescence in situ hybridization","volume":"158","author":"Slovak\n ML,","year":"2005","unstructured":"Slovak\n ML, \n \n Bedell\n V, \n \n Pagel\n K, \n et al\n . Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype\/genotype fluorescence in situ hybridization. Cancer Genet Cytogenet. 2005;158(2):99\u2013109."},{"issue":"2","key":"i1543-2165-137-5-625-b30","series-title":"Cancer Genet Cytogenet","first-page":"112","article-title":"Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment","volume":"189","author":"Pozdnyakova\n O,","year":"2009","unstructured":"Pozdnyakova\n O, \n \n Crowley-Larsen\n P, \n \n Zota\n V, \n et al\n . Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment. Cancer Genet Cytogenet. 2009;189(2):112\u2013117."},{"key":"i1543-2165-137-5-625-b31","series-title":"Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed","first-page":"200","article-title":"Plasma cell neoplasms","author":"McKenna\n RW,","year":"2008","unstructured":"McKenna\n RW, \n \n Kyle\n RA, \n \n Kuehl\n WM, \n et al\n . Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press;2008:200\u2013213. World Health Organization Classification of Tumours; vol 2."},{"key":"i1543-2165-137-5-625-b32","series-title":"Am J Clin Pathol","first-page":"391","article-title":"Chromosome 20q deletion: a recurrent cytogenetic abnormality in chronic myelogenous leukemia patients in remission","volume":"135","author":"Sun\n J,","year":"2011","unstructured":"Sun\n J, \n \n Yin\n C, \n \n Cui\n W, \n \n Chen\n SS, \n \n Medeiros\n LJ, \n \n Lu\n G. \n \n Chromosome 20q deletion: a recurrent cytogenetic abnormality in chronic myelogenous leukemia patients in remission. Am J Clin Pathol. 2011;135:391\u2013397."},{"issue":"1","key":"i1543-2165-137-5-625-b33","series-title":"Cancer Genet Cytogenet","first-page":"56","article-title":"Genetic and immunophenotypic profile of IgH rearrangement detected by FISH in 149 cases of chronic lymphocytic leukemia","volume":"196","author":"Lu\n G,","year":"2010","unstructured":"Lu\n G, \n \n Kong\n Y, \n \n Yue\n C. \n \n Genetic and immunophenotypic profile of IgH rearrangement detected by FISH in 149 cases of chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2010;196(1):56\u201363."},{"issue":"5","key":"i1543-2165-137-5-625-b34","series-title":"Int J Lab Hematol","first-page":"545","article-title":"Assessment of bone marrow plasma cells by flow cytometric and fluorescence in situ hybridization evaluations in 244 cases of plasma cell neoplasms","volume":"3","author":"Lu\n G,","year":"2011","unstructured":"Lu\n G, \n \n Zhang\n XX, \n \n You\n J, \n \n Chen\n W. \n \n Assessment of bone marrow plasma cells by flow cytometric and fluorescence in situ hybridization evaluations in 244 cases of plasma cell neoplasms. Int J Lab Hematol. 2011;3(5):545\u2013550."},{"issue":"suppl 4","key":"i1543-2165-137-5-625-b35","series-title":"Clin Lymphoma Myeloma","first-page":"S170","article-title":"Individualizing therapy using molecular markers in multiple myeloma","author":"Bergsagel\n PL.","year":"2007","unstructured":"Bergsagel\n PL. \n \n Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma. 2007;(suppl 4):S170\u2013S174."},{"issue":"5","key":"i1543-2165-137-5-625-b36","series-title":"Int J Hematol","first-page":"516","article-title":"Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed\/refractory multiple myeloma","volume":"95","author":"Kiyota\n M,","year":"2012","unstructured":"Kiyota\n M, \n \n Kobayashi\n T, \n \n Fuchida\n S, \n et al\n . Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed\/refractory multiple myeloma. Int J Hematol. 2012;95(5):516\u2013526."}],"container-title":["Archives of Pathology and Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/137\/5\/article-p625.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/137\/5\/625\/1612383\/arpa_2012-0209-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/137\/5\/article-p625.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/137\/5\/article-p625.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:59:16Z","timestamp":1770771556000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/137\/5\/article-p625.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":72,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2012-0209-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}